P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

Bibliographic Details
Main Authors:	Abu-Sayeef Mirza, Alexander Pine, Ramzi Hamouche, Yusuf Rasheed, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred Lee, Stuart Seropian
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972412.18474.98

Similar Items

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
by: Yusuf Rasheed, et al.
Published: (2023-08-01)

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
by: Guido Ghilardi, et al.
Published: (2024-04-01)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-07-01)

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
by: Saurabh Zanwar, et al.
Published: (2024-06-01)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-10-01)

Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)

Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
by: Audrey Couturier, et al.
Published: (2024-07-01)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
by: Albert Oriol, et al.
Published: (2021-05-01)

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
by: Maximilian Merz, et al.
Published: (2025-01-01)

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
by: Jamie N. Connarn, et al.
Published: (2023-11-01)

Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient
by: Dasom Lee, et al.
Published: (2024-02-01)

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
by: Yuliya Linhares, et al.
Published: (2024-12-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
by: Surbhi Sidana, et al.
Published: (2023-09-01)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
by: Sundar Jagannath, et al.
Published: (2021-06-01)

Comparative efficacy of lisocabtagene maraleucel in the PILOT study <i>versus</i> second-line chemotherapy regimens in the real world
by: Nilanjan Ghosh, et al.
Published: (2024-10-01)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
by: Shinichi Makita, et al.
Published: (2022-12-01)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
by: Franziska Marquard, et al.
Published: (2023-11-01)

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
by: Leo I. Gordon, et al.
Published: (2023-08-01)

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
by: Loretta J. Nastoupil, et al.
Published: (2025-03-01)

106 Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel)
by: Susan Kim, et al.
Published: (2021-11-01)

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
by: Ricardo D. Parrondo, et al.
Published: (2022-04-01)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
by: Dilara Akhoundova Sanoyan, et al.
Published: (2023-04-01)

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
by: Hamza Hashmi, et al.
Published: (2023-10-01)

P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121)
by: J. Rytlewski, et al.
Published: (2022-06-01)

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
by: Julie Rytlewski, et al.
Published: (2021-11-01)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
by: Guillaume Cartron, et al.
Published: (2022-03-01)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
by: P Rodríguez-Otero, et al.
Published: (2022-04-01)

P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C
by: Melissa Alsina, et al.
Published: (2023-08-01)

S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY
by: A. Sehgal, et al.
Published: (2022-06-01)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
by: P. Rodríguez-Otero, et al.
Published: (2023-05-01)

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
by: Julia Piasecki, et al.
Published: (2023-08-01)

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY
by: N. Shah, et al.
Published: (2022-06-01)

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
by: Krina Patel, et al.
Published: (2023-08-01)

P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE
by: N. Martin, et al.
Published: (2022-06-01)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
by: L. I. Gordon, et al.
Published: (2022-06-01)

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
by: Salomon Manier, et al.
Published: (2023-08-01)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
by: P Rodríguez-Otero, et al.
Published: (2022-04-01)

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
by: Michel Delforge, et al.
Published: (2023-08-01)

Genoese-Tatar Treaties of 1380 and 1381 in Their Historical Context.
by: Talakh V.N.
Published: (2021-03-01)